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Available online 6 March 2014Abstract Human bone marrow stromal cells (hBMSCs, also known as bone marrow-derived mesenchymal stem cells) are
promising tools for the cellular therapy of human pathologies related to various forms of hypoxia. Although the current
concepts of their clinical use include the expansion of hBMSC in standard cell culture conditions, the effect of the
mitogen-driven ex vivo expansion on the adaptation to the hypoxic environment is unknown. Here, we provide data that the
basic fibroblast growth factor (FGF2) enhances the induction of a wide range of hypoxia-related adaptive genes in hypoxic
hBMSCs. We identified that the FGF2 signal is transmitted by the ERK pathway similar to that of hypoxia that also utilises the
distal elements of the same signalling machinery including the extracellular signal-regulated kinase 1/2 (ERK1/2) and
mitogen-activated protein kinase kinases (MEK1/2) in hBMSCs. We found that the simultaneous activation of ERK1/2 by FGF2
and hypoxia transforms the activation dynamics from oscillatory into sustained one. Activated ERKs co-localise with stabilised
hypoxia inducible factor-1α (HIF-1α) followed by the reduction of its nuclear mobility as well as increased DNA binding capacity
leading to the up-regulation of hypoxia-adaptive genes. Our findings indicate that the status of the ERK pathway has significant
impacts on the molecular adaptation of hBMSCs to the hypoxic milieu.© 2014 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.⁎ Corresponding author at: Regenerative Medicine Institute,
National University of Ireland Galway, Galway, Republic of Ireland.
Fax: +353 91 494 596.
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http://dx.doi.org/10.1016/j.scr.2014.02.007
1873-5061/© 2014 The Authors. Published by Elsevier B.V. Open aIntroductionccess unCultures of human bone marrow stromal cells (hBMSCs, also
known as human bone marrow-derived mesenchymal stemder CC BY-NC-ND license.
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stem cells) with the capacity to differentiate into a variety
of cell types including chondrocytes, osteoblasts or adipo-
cytes (Dominici et al., 2006; Pittenger et al., 1999). They are
believed to have a great medical potential in a range of
human pathologies especially those that require the regen-
eration of the bone and cartilage (Robey and Bianco, 2006).
Despite the different pathogenesis, local hypoxia is considered
to be a critical factor in a number of medical conditions
affecting these tissues. In experimental conditions, hBMSCs
efficiently adapt to low oxygen environments by adjusting their
gene expression and metabolism to the hypoxic conditions that
results in enhanced proliferation and differentiation (Grayson
et al., 2007; Kanichai et al., 2008). These observations further
fuelled the idea that hBMSC cultures are particularly useful for
cellular therapy of oxygen-depleted tissues.
The current concepts of the hBMSCs-based cellular therapies
include the in vitro expansion of the cells for, at least, two
reasons. On the one hand, one of the minimal criteria for
defining hBMSCs is their adherence to plastic in standard
cell culture conditions (Dominici et al., 2006). On the other,
in vivo studies suggest that aminimumof 107–1011 transplanted
hBMSCs are required for clinically evaluable efficacy (Chen
et al., 2004; Macmillan et al., 2009; Mazzini et al., 2010;
Perez-Simon et al., 2011). Thus, due to their limited ex vivo
proliferation capacity, the hBMSC culture media are commonly
supplemented with mitogenic factors including the basic
fibroblast growth factor (FGF2) (Martin et al., 1997).
The ubiquitously expressed FGF2 is the prototypic
member of the paracrine group of human FGFs (Beenken
and Mohammadi, 2009). Its endogenous expression is
regulated at multiple levels including the alternative
translation of polypeptides that eventually differ in size
(18–34 kDa), domain structure and intracellular localization
(Yu et al., 2007). Although experimental results suggest the
function of FGF2 in angiogenesis and the regulation of the
vascular tone, its physiological roles remain unclear as
FGF1−/− and FGF2−/− double knock-out mice are completely
viable and fertile showing only minor defects in brain
development, haematopoiesis and wound healing (Cuevas
et al., 1991; Fulgham et al., 1999; Miller et al., 2000; Zhou
et al., 1998). FGFs signal via structurally related cell surface
receptors (FGFR1-5) that, apart from FGFR5, function as
receptor tyrosine kinases (Mohammadi et al., 2005; Sleeman
et al., 2001). The multiple isoforms of FGFR1-3 generated by
exon skipping and alternative splicing have different ligand
specificity and tissue-specific expression (Eisemann et al.,
1991; Johnson et al., 1991). The signalling machinery of
FGFs is similarly complex and, based on literature data,
linked to the PLCγ1, the PKB/Akt and the ERK pathways alike
(Chen et al., 2000; Chikazu et al., 2000; Park et al., 1999).
The effects of the 18 kDa species of FGF2 used on hBMSC
include the preservation of their fibroblast morphology as
well as proliferation and differentiation capacity (Martin
et al., 1997). Interestingly, these effects are similar to those
of hypoxia on FGF-naïve hBMSCs including the enhanced
proliferation, prevented senescence, up-regulated metabo-
lism and, apart from the osteogenic lineages, increased
differentiation efficiency (Grayson et al., 2007; Kanichai
et al., 2008; Tsai et al., 2011; Volkmer et al., 2010).
The primary intracellular sensors of hypoxia are the prolyl
hydroxylase enzymes (PHDs) that, utilising oxygen as co-factor,hydroxylate critical proline residues of their substrates (Willam
et al., 2004). PHDs target the basic helix-loop-helix transcrip-
tion factor hypoxia inducible factor-1 (HIF-1) (Wang et al.,
1995). Active HIF-1 consists of one alpha and one beta subunits
that are constitutively translated in most cells types (Wang
and Semenza, 1995). PHD-mediated prolyl hydroxylation of
the alpha subunit, however, induces its ubiquitination and
proteasomal degradation preventing the formation of the
active HIF-1α/β heterodimers (Chan et al., 2002; Ivan et al.,
2002; Masson et al., 2001). In contrast, under hypoxic
conditions, PHDs become inactive leading to the accumulation
of the functional HIF-1 heterodimers. Once stabilised, active
HIF-1 alters the transcriptional pattern to facilitate cellular
adaptation to the hypoxic milieu (Majmundar et al., 2010).
Although the molecular machinery orchestrating the biolog-
ical responses to hypoxia at the transcriptional level is well
detailed, the relationship between the FGF2 and hypoxia
signalling in hBMSCs has remained unexplored. The similar
effects of FGF2 and hypoxia on hBMSC cultures, however,
suggest that the two stimuli utilise, at least in part, the same
molecular machinery. This raises the question if the use of FGF2
upon the in vitro expansion of hBMSCs has an impact on the
hypoxic adaptation of the same. We investigated this question
by combining methodologies of molecular biology and biophys-
ics. Here, we provide data that FGF2 enhances the expression of
genes critical in themetabolic adaptation to hypoxia. We found
that both FGF2 and hypoxia signal through the ERK pathway and
the two signals are merged upstream of the mitogen activated
protein kinase kinase (MEK). The simultaneous activation of the
ERK pathway in FGF2-cultured hypoxic hBMSCs leads to altered
signalling dynamics and enhanced HIF-1α DNA binding activity.
We found that the latter effect is mediated post-translationally
by direct interaction of the activated ERK and stabilised HIF-1α
proteins.We also provide data that FGF2 not only facilitates the
reduction of the nuclear mobility of HIF-1α but also results in
modified complex formation in hypoxic cells.Materials and methods
Cell cultures and chemicals
Plastic adherent human bone marrow stromal cells were
obtained from bone marrow aspirates taken from the iliac
crest of healthy donors. All procedures were performed with
informed consent and approved by the Clinical Research
Ethical Committee at University College Hospital, Galway.
Bone marrow aspirates were diluted in 1× Dulbecco's
Phosphate-Buffered Saline (DPBS; Life Technologies) in 1:1
ratio and centrifuged at 800 g for 10 min. Supernatant was
removed and cells were re-suspended in 1× DPBS. Test sample
was taken from the suspension, diluted in 1:10 ratio in 1× DPBS
andmononuclear cells were counted using 4% acetic acid (1:1).
For FGF2-treated cultures, 8.75 × 106 mononuclear cells per
T-175 flask were plated in alpha-Minimum Essential Medium
(α-MEM; Life Technologies) containing 10% pre-screened foetal
bovine serum (FBS; Hyclone, South Logan, UT, USA), mixture of
penicillin/streptomycin (1%) and supplemented with 1 ng/mL
recombinant 18 kDa human basic fibroblast growth factor
(FGF2; PeproTech, UK). For FGF2-naïve cultures, approximate-
ly 4.0 × 107 mononuclear cells per T-175 flask were plated in
α-MEM containing 10% pre-screened foetal bovine serum (FBS;
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streptomycin (1%). Cultures weremaintained at 37 °Cwith 95%
humidity and 5% CO2 in the same medium for 5 days. Following
incubation, non-adherent cells were washed off with 1× DPBS
and fresh medium was added. Colonies of adherent cells
usually formed within 9 days were detached using 0.25%
trypsin/0.53 mM ethylenediaminete-tetraacetic acid (EDTA)
solution. U-2 OS human osteosarcoma cells were maintained in
Dulbecco's Modified Eagle Medium (DMEM) with 4500 mg/L
glucose and 4 mM L-Glutamine supplemented with 10% heat-
inactivated FBS and 1% penicillin/streptomycin. Phenol-red
containing culture media was replaced with phenol-red free
DMEM supplemented as detailed above 24 h before fluorescent
correlation spectroscopy. U-2 OS cells stably expressing the
eGFP-tagged HIF-1α were established using the Gateway
cloning system (Invitrogen) with HIF-1α cDNA (Genepodia)
carrying entry and pIC113-based eGFP vectors (pIC113gw
from Prof. K. Sullivan). All chemicals were purchased from
Sigma-Aldrich unless otherwise stated. U0126 was purchased
from Calbiochem.
Flow cytometry
Isolated hBMSCs (105/antibody) were blocked on ice in PBS with
2% FBS for 30 min. After centrifugation the cells were resus-
pended in 50 μL of phycoerithrin-conjugated antibody (Table S2)
and incubated on ice for 30 min. Cells were thenwashed twice in
1 × DPBSwith 2% FBS prior to analysis on a BD FACS Canto II. Data
were analysed using FloJo software (Fig. S1A).
Functional characterization of hBMSCs
Functional characterization of hBMSCswas carried out by testing
the adipo-, osteo- and chondrogenic capacity of the cells (Figs.
S1B–D). Adipogenesis was induced in confluent cultures by
incubating the cells in adipogenic induction and maintenance
media for 3 days and 1 day, respectively (formedia composition
please see Tables S3 and 4). Media replacement was repeated 3
times finally leaving the cultures in maintenance medium for
5 days. Cells then were fixed and stained with Oil Red O.
Osteogenesis was induced in confluent cultures incubated in
osteogenic medium (Table S5) for 10–17 days. Osteogenically
differentiated cultures were fixed and stained for accumulated
calcium with Alizarin Red. Accumulated calcium was quantified
using the Calcium CPC liquicolor kit (Stanbio) as per the
manufacturer's instructions. Chondrogenesis was induced in
pellet cultures (Johnstone et al., 1998) of 2.5 × 105 cells using
chondrogenic medium (Table S6). After 21 days of incubation,
pellets were either fixed, sectioned and stained with Safranin-O
for glycosaminoglycans (GAG) or Papain digested for quantifica-
tion of the GAG content using 1,9-dimethyl methylene blue
(DMMB) as described previously (Enobakhare et al., 1996). GAG
values were normalised to cell numbers by measuring the DNA
content of the pellet cultures using Pico green assay (Invitrogen)
as per the manufacturer's instructions.
Measuring the population doubling times of hBMSC
Passage four hBMSCs were plated on 6-well plates in 3 × 104
cell/well density and cultured for 4 days. Following incubation
the cells were trypsinised, collected by centrifugation (400 gfor 5 min at RT) and re-suspended in 1 mL complete culture
media. Cell counting was performed in a haemocytometer.
Cells were then re-plated on fresh plates as above and steps
were repeated until the cultures reached passage six.
Immunofluorescent confocal microscopy
Immunofluorescent confocal microscopy was carried out
on cells grown on 96-well μ-Plate plates from Integrated
BioDiagnostics (Germany). Cells were fixed in 4% paraformal-
dehyde (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) for
15 min at room temperature (RT) and washed three times in
1× PBS for 5 min at RT. Cells were permabilized in 1× PBS with
0.1 Triton X-100 for 15 min at RT and washed three times in 1×
PBS for 5 min at RT. Specimens were blocked in 1× PBS with
20% normal goat serum and 0.1% Triton X-100 (0.2NGS-PBST)
overnight at 4 °C and subsequently incubated in 0.2NGS-PBST
containing the anti-phospho-ERK1/2 antibody or normal rabbit
serum (negative control) in 1:100 dilution and Alexa Fluor®
647-labelled phalloidin in 1:20 dilution overnight at 4 °C. Cells
were washed in 1× PBS 5 times for 5 min at RT and incubated
in 0.2NGS-PBST containing the Alexa Fluor 594 goat anti-rabbit
IgG (H + L) secondary antibody in 1:200 dilutions for 1 h at
4 °C. Following extensive washing steps, counter staining was
performed using 100 μL/well 1× PBS containing 1 μg/mL
Hoechs33342 for 1 min at RT. Hoechs33342 was washed out
and wells were filled up with 100 μl 1× PBS. Hoechs33342 and
AlexaFluor 647-conjugated phalloidin was obtained from Life
Technologies Ireland.
Immunoblot
Immunoblot analyses were done as detailed in (Fabian et al.,
2009). Primary antibodies used are summarised in Table S2.
Species-specific secondary antibodies were purchased from
Thermo Scientific. Chemiluminescent signals were detected
by FluorChem digital imaging system.
Real-time RT-PCR
Total RNA was isolated using Trizol reagent (Invitrogen) as per
the manufacturer's instructions. Concentrations and integrity
of RNA isolates were determined by Nanodrop ND-1000
spectrophotometer (NanoDrop Technologies) and Agilent
2100 Bioanalyzer (Agilent), respectively. cDNA synthesis and
real-time PCR analysis of samples were performed using High
Capacity cDNA Reverse Transcription Kit and TaqMan® Fast
Universal PCR Master Mix (Applied Biosystems). Real time PCR
reactions were carried out using StepOnePlus thermal cycler
(Applied Biosystems). Expression levels were calculated by
the delta delta Ct (ΔΔCt) method using Lamin A-specific
primers and probes as endogenous control and ROX as passive
reference dye. Primers and probes were purchased from
Applied Biosystems's gene expression assay library. Used
assays are summarised in supplementary Table 7 (Table S7).
ELISA-based DNA binding assay
HIF-1α DNA-binding activity was determined using the
HIF-1α specific TRANS-AM kit from Active Motif as per the
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by measuring the absorbance of the reaction mixture at
450 nm using Wallac 1420 VICTOR2 microplate reader
(Perkin Elmer).Proximity ligation assay (PLA)
PLA was carried out using the DuoLink labelling system
from Sigma according to the manufacturer's instructions.
Primary antibodies used were mouse monoclonal
anti-HIF-1α (BD; 1:80 dilution) and rabbit monoclonal
phospho-specific anti-p42/44 or anti-HIF-1β (Cell Signal-
ling; 1:80 and 1:800 dilutions, respectively). For nuclear
counter staining, samples were stained with 0.5 μg/mL
Hoechst33342 for 1 min at RT. Amplification was detected
using DAPI and TRITC filters of an Olympus IX81 inverted
epifluorescent microscope. Pictures were recorded by
Volocity software.Real-time fluorescent correlation spectroscopy (FCS)
FCS measurements were carried out using an FV1000
confocal microscope (Olympus, Germany) equipped with an
FCS module (Picoquant, Germany) at λex 473 nm and λem
515–550 nm wavelengths. Emitted fluorescence was focused
onto a single photon avalanche diode (Micro Photon Devices,
Italy) using a 100 μm pinhole. Fluorescence fluctuations
(raw data) were acquired by Symphotime software
(Picoquant, Germany). Autocorrelation function (G(τ))
(time-dependent decay) was calculated from fluorescence
fluctuation intensity as G(τ) = ((ΔF(τ) ∙ ΔF(t + τ)) / F(t)2),
where F(t) is the temporal average of the signal; ΔF(t) is the
fluctuation of fluorescence signal defined as deviation from
F(t); and ΔF(t + τ) is the fluctuation of fluorescence signal at
t + τ deviation from F(t). Measurements were done at 2
randomly selected nuclear positions. Autocorrelation mea-
surements were performed on both spots 6 times for 10 s
(Fig. S2). Data with unusual variation or oscillation in the
count rates or average photon count rate per second ≤1200
were excluded from further analysis. Autocorrelation curves
fitting and the calculation of the average dwell time of the
fluorescent species (τD) within the observation volume were
carried out as described in (Brazda et al., 2011; Broderick et
al., 2012). The diffusion coefficient (D) of the eGFP-tagged
HIF-1α was calculated as D = ω2/4τD. The lateral radius of
the observation volume (ω = 0.25 μm) was calculated after
calibration using water-dissolved atto488 fluorescent dye
(20 nM) (ATTO GmBH, Germany). Diffusion coefficient of the
atto488 dye was taken from (Dertinger et al., 2007).Statistical analysis
Experimental values are expressed as mean value ± SD. For
significance analyses, mixed ANOVA was performed. Multiple
comparisons were done using Tukey's post-hoc tests with
Bonferroni's confidence interval adjustment. P-values ≤0.05
(*), ≤0.01 (**) and ≤0.001 (***) were considered significant,
highly significant and extremely significant, respectively.Results
FGF2 enhances the effects of hypoxia in hBMSCs
To test if the in vitro mitogenic pressure interferes with the
hypoxic response of hBMSCs,wemonitored the proliferation of
normoxic and hypoxic cells in the presence or absence of FGF2
by measuring the mean population doubling times (PDT). In
accordance with the literature data, FGF2-naïve normoxic
cultures ceased to proliferate at passage 5 and 6 showing
99.4 ± 20.9 and 169.3 ± 25.2 h of PDT, respectively, com-
pared to their early passage PDT of 49.5 ± 4.3 h (Fig. 1A).
Simultaneously, cells lost their original fibroblast-like pheno-
type and adopted unusual morphologies towards the late
passages (Fig. 1B). In contrast, hBMSCs cultured in FGF2-
supplemented media escaped from senescence and preserved
the fibroblast phenotype even at late passages. Similarly,
FGF2-cultured hBMSCs had significantly reduced PDTs (33.7 ±
3.5, 28.4 ± 2.9 and 43.5 ± 20.4 h at P4, P5 and P6, respec-
tively) compared to the FGF2-naïve cultures over the culturing
period observed. Culturing hBMSCs in low oxygen environment
had similar effects; cells maintained both constant cell cycle
speeds (47.4 ± 0.9, 48.5 ± 4.9 and 55.8 ± 7.4 h at P4, P5 and
P6, respectively) and typical hBMSC morphology. Hypoxia-
induced proliferation, however, was slightly but significantly
slower in the early passage cultures than that of the
FGF2-cultured normoxic hBMSCs. Combination of FGF2 and
hypoxia had similar effect on hBMSC morphology as the
two stimuli alone. Interestingly, FGF2-treatment of hypoxic
hBMSCs led to a further reduction of PDTs (28.7 ± 1.6, 32.5 ±
2.9 and 30.8 ± 1.8 h at P4, P5 and P6, respectively)
compared to the FGF2-naïve hypoxic cultures. By contrast,
hypoxia did not have additive effect on hBMSC proliferation;
both FGF2-cultured normoxic and hypoxic cultures had
comparable PDTs. To test if FGF2 alters the hypoxic
adaptation of hBMSCs at the molecular level, we measured
the expression of selected hypoxia-related genes in hBMSCs.
We found that the expression of the glucose transporter
encoding SLC2A1 and the intracellular pH regulator carbonic
anhydrase IX encoding CA9 genes were both significantly
up-regulated in FGF2-cultured hypoxic hBMSCs compared
to their FGF2-naïve counterparts (Figs. 1C-D). The induction
of SLC2A1 and CA9 were 3- and 10-fold higher, respectively,
in FGF2-cultured cells compared to the FGF2-naïve cultures
at the end of the 24 hour time course. While the SLC2A1
relative expression levels were not significantly different
in normoxic cells, an approximately 6-fold induction of the
basal expression of CA9 was measured in FGF2-cultured
hBMSC cultures over the FGF2-naïve ones under normoxic
conditions. Screening the transcriptionally regulated mem-
bers of the glycolytic genes revealed similar trends in the
expression of the triosephosphate isomerase (TPI1), glycerol
3-phosphate dehydrogenase (GPDH), phosphoglycerate kinase
(PGK1) and enolase (ENO) (Fig. 1E and Fig. S3). The up-
regulation was 2 to 3-fold higher in the presence of FGF2
compared to the FGF2-naïve cultures as early as 4–8 h
post-exposure. Similar to CA9, the up-regulation of the basal
gene expression of the TPI1, GPDH, PGK1 and ENO was also
observed in the FGF2-cultured normoxic cells. To a lesser
extent, lactate dehydrogenase was also up-regulated in
FGF2-cultured hBMSCs but no similar effect was measured
in the expression of pyruvate kinase (data not shown). These
Figure 1 Effects of FGF2 and hypoxia on hBMSC cultures. (A) Population doubling times of hBMSC cultures. Cells were cultured both
in the presence (grey and striped bars) or absence (black and white bars) of FGF2 (1 ng/mL) at atmospheric or 2% O2 levels and
population doubling times (PDT) were monitored. PDT values are expressed as mean ± SD (n = 3). (B) Phase-contrast microscopic
analysis of cultures kept at atmospheric (B1 and B2) or 2% O2 (B3 and B4) in the absence (B1 and B3) or presence (B2 and B4) of 1 ng/mL
FGF2. Images were taken using 10× dry objective lens. Scale bar: 200 μm. (C–E) Expression of hypoxia-related metabolic genes in
hBMSC. Cells were cultured in the presence (▮) or absence (▯) of 1 ng/mL FGF2 at atmospheric or 1% O2 levels for times indicated in
the figure. Expression of hypoxia-related metabolic genes (C: glucose transporter [SLC2A1]; D: carbonic anhydrase IX [CA9];
E: phosphoglycerate kinase [PGK-1]) was measured by real time RT-PCR. Gene expression levels are presented as mean fold change to
normoxic FGF2-naïve cultures ± SD (n = 3).
Figure 2 FGF2 and hypoxia activates the ERK pathway in hBMSC. (A) Immunoblot analysis of the phosphorylation of ERK1/2 in
FGF2-treated hBMSC. (B) Immunofluorescent detection of the nuclear accumulation of p-ERK1/2 (Thr202/Tyr204) in FGF-naïve
hBMSC. Nuclei were counterstained using 1 μg/mL Hoechs33342. f-Actin was labelled by AlexaFluor 647-conjugated phalloidin. White
arrows indicate positive nuclei. Images were taken using 60× oil immersion objective lens. Scale bar: 10 μm. (C) Immunoblot analysis
of the phosphorylation of ERK in hypoxic hBMSCs. Cells were treated with 1 ng/mL FGF2 and 10 μM U0126 as indicated in the figure for
120 min. U0126-treatments preceded the addition of FGF2 by 30 min. (D) Immunoblot analysis of the activation of the ERK pathway in
hypoxic hBMSCs. Accumulation of HIF-1α was used as marker of the cellular response to hypoxia. (E) Simultaneous signalling by FGF2
and hypoxia alters the kinetics of the ERK1/2 activation and the HIF-1α accumulation. FGF2-naïve (left panels) and FGF2-cultured
(right panels) hBMSCs were exposed to hypoxia (1% O2) for times indicated in the figure. ERK1/2 phosphorylation and HIF-1α
accumulation was monitored by immunoblot. NUCLEOLIN and LAMIN B1 were used as loading controls. (F) Densitometry analysis of
Fig. 2E. Loading control-normalised data are expressed as fold change of normoxic cultures.
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652 Z. Fábián et al.data indicate that FGF2 enhances the hypoxic response of
hBMSCs at the transcriptional level.Both FGF2 and hypoxia utilise the distal elements of
the ERK pathway for immediate signal transduction
in hBMSCs
To identify the signalling pathway conveying the FGF2
signal to the transcriptional level in hBMSCs, we tested the
phospholipase C gamma 1 (PLCγ1), protein kinase B (PKB/
Akt) and extracellular signal-regulated protein kinase (ERK)
pathways as the main signalling systems believed to be
responsible for transducing the receptor-mediated FGF
signals. Immunoblot analysis showed that PLCγ1 was not
detectable in hBMSC cultures (Fig. S4A). PKB/Akt was
detectable and hypoxia induced activation phosphorylation
at Thr308 at 2 h post-exposure indicating the responsiveness
of the PKB/Akt system in hBMSCs. However, no activating
phosphorylation of PKB/Akt was observed in FGF2-treated
normoxic hBMSCs (Fig. S4B). By contrast, immunoblot
analysis of ERK1/2 showed rapid phosphorylation at positions
Thr202 and Tyr204 of, primarily, ERK2 in a biphasic manner
over the first 3 h of the treatment (Fig. 2A). The nuclear
accumulation of phosphorylated ERK1/2 occurs within
15 min after the exposure of FGF2-naïve hBMSCs to FGF2
(Fig. 2B). As expected, this effect was blocked by the use
of the pharmacological MEK inhibitor U0126 indicating a
canonical FGF2-mediated activation of ERKs (Fig. 2C).
Similar to FGF2, hypoxia induced biphasic ERK1/2 activation
in hBMSCs that could be blocked by U0126 indicating that
both FGF2 and hypoxia activate ERK1/2 via MEK (Fig. 2D).
Unlike ERK1/2, however, MEK phosphorylation at positions
Ser217 and 221 was found transient reaching the maximum
and then returning to its basal phosphorylation levels at 30
and 90 min post-exposure, respectively. In contrast, phos-
phorylation of MEK remained sustained in U0126-treated
cells, at least, up to 210 min post-exposure. In hypoxic
hBMSCs, levels of the hypoxia marker HIF-1α increased 5–6
folds compared to the normoxic cultures by 120–150 min
post-exposure. Following the maximum accumulation, HIF-
1α levels decreased towards the end of the time course. In
contrast, blockade of ERK signalling by MEK inhibition led to
reduced rate of HIF-1α accumulation that, however,
increased during the 210 min of the hypoxic exposure
(Fig. 2D). To test the effects of the simultaneous stimulation
of the ERK pathway by FGF2 and hypoxia on the activation of
ERK1/2 and HIF-1α, we monitored the ERK1/2 phosphoryla-
tion and HIF-1α accumulation over a 24 hour time course.
Hypoxia induced ERK1/2 phosphorylation was detectable in
both FGF2-naïve and FGF2-cultured cells (Fig. 2E). The
dynamics of the ERK1/2 activation, however, was different;
FGF-naïve hBMSCs displayed periodicity in the levels of
the phosphorylated ERK1/2 over the first 24 h of hypoxia
treatment. In contrast, the presence of FGF2 in the culture
medium altered the activation dynamics and resulted in a
more sustained activation of ERK1/2. HIF-1α was accumu-
lated in both cultures but its stabilisation was delayed and
lasted for a shorter time in FGF2-naïve cultures. Our findings
indicate that both FGF2 and hypoxia utilise the ERK pathway
but the simultaneous presence of the two stimuli alters boththe activation dynamics of ERK1/2 and the accumulation of
HIF-1α in hypoxic hBMSCs.FGF2 does not perturb the transcriptional and
PHD-mediated regulation of HIF-1α but leads to
its co-localisation with activated ERKs in
hypoxic hBMSCs
Based on data from cell free, yeast and established cell line
model systems, there are different speculations on the link
between the ERK and HIF-1α pathways (Bardos et al., 2004;
Mylonis et al., 2008; Richard et al., 1999; Sang et al., 2003).
To study this question in hBMSCs, we tested if FGF2 alters
the oxygen sensitivity of hBMSCs by exposing cells to
increasing levels of hypoxia. Cells cultured in normoxic
conditions for 3 passages were first exposed to 6% O2 for
120 min. Following incubation, samples were collected and
the oxygen level was further decreased for the remaining
cells by 1% for an additional 120 min. Steps were repeated
five times and samples were tested for HIF-1α (Figs. 3A–B).
We found that HIF-1α was weakly accumulated in both
cultures when normoxic cells were exposed to the 6% oxygen
environment. However, this initial HIF-1α response became
undetectable in cells incubated further at 5% and 4% oxygen
levels. Stable accumulation of HIF-1α occurred at 3% oxygen
in both FGF2-naïve and FGF2-cultured cells indicating
that FGF2 does not elevate the oxygen sensitivity of hBMSCs.
The literature data also indicate that in certain conditions
HIF-1α can be regulated transcriptionally (Bruning et al.,
2011; Fitzpatrick et al., 2011). To study this scenario, we
measured the HIF-1α expression in hypoxic hBMSCs both in the
presence or absence of FGF2. We found a 2–3 fold increase in
the basal expression of HIF-1α in FGF2-cultured normoxic
hBMSCs compared to the FGF2-naïve cells (Fig. 3C). However,
FGF2-treatment of the latter cells revealed no immediate
induction of HIF-1α in the first 48 h of treatment (Fig. 3D).
In addition, we also found that the known post-exposure
down-regulation of the HIF-1α mRNA levels was not affected
by FGF2 (Bruning et al., 2011). Together, these data indicate
that FGF2 has no direct effects on either the PHD-mediated
post-translational or the transcriptional regulation of HIF-1α.
To further investigate the relationship between activated
ERKs and HIF-1α, we tested if the phosphorylated ERK1/2
binds HIF-1α directly in hypoxic hBMSCs by in situ proximity
ligation assay (PLA) (Fig. 3E). As positive control, FGF2-naïve
hBMSCs were treated with N-(methoxyoxoacetyl)-glycine
methyl ester (DMOG) to stabilise HIF-1α in normoxic cells. In
DMOG-treated cells, PLA was carried out using HIF-1α and
HIF-1β-specific antibodies. As expected, DMOG-treated cells
showed robust PLA signals indicating the nuclear formation of
HIF-1α/β heterodimers. In untreated normoxic FGF-naïve
hBMSC cultures, we could not detect PLA signals using primary
antibodies specific to phosphorylated ERK1/2 and HIF-1α. In
FGF2-treated hypoxic hBMSCs, however, PLA was positive
with strong amplification signals in the majority of FGF2-
treated hypoxic hBMSCs at 30 min post-exposure indicating
the proximity of the activated ERK1/2 and HIF-1α with the
maximum theoretical distance of 30–40 nm. Interestingly,
however, although themajority of the phospho-ERK1/2-HIF-1α
signals showed nuclear localisation, signals were also detected
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two molecules in the cytoplasm as well.
FGF2-treatment results in reduced nuclear diffusion
and increased DNA-binding activity of HIF-1α
To further study the impact of the activated ERK1/2 on
HIF-1α, we measured the mobility dynamics of HIF-1α usinglive cell fluorescence correlation spectroscopy (FCS). The
advantage of this method is that it provides quantified data
on the mobility of the fluorescently tagged target molecule
in real-time that directly correlates to the formation of
molecular complexes, a critical aspect of the activation
of HIF-1α. For FCS analysis, however, the concentration of
fluorescent molecules must be within the range of 10–50 nM
(maximum 100 nM) to provide high enough signal-to-noise
ratios with still detectable fluorescent fluctuations. In
addition, cells should be flat enough to make the examined
confocal volume stable for the measurements. Unfortunate-
ly, due to the limited life span, morphology and poor
susceptibility to non-viral transfections of the human bone
marrow stromal cultures, we failed to establish an eGFP-
HIF-1α–carrying hBMSC clone compatible to the absolute
requirements of FCS. Instead, considering its physical
properties, responsiveness to FGF2 and different dynamics
of the ERK activation in the presence or absence of FGF2
under hypoxia, the histologically related U-2 osteosarcoma
cell line was chosen to serve as model system (Fig. S5). For
FCS, U-2 OS cells were stably transfected with a construct
encoding the HIF-1α that was N-terminally tagged with eGFP
(U-2 OSeGFP-HIF-1α) and clones with eGFP-HIF-1α levels most
appropriate for FCS was selected (U9eGFP-HIF-1α). U9eGFP-HIF-1α
cells were exposed to 1% O2 in the presence or absence of
FGF2 and U0126 and subjected to FCS. In FGF2-naïve cells,
significant reduction in the diffusion coefficient (DeGFP-HIF-1α)
of HIF-1α was first detected at 4 h post-exposure in the
nucleus when approximately 5% and 10% of the cells showed
diffusion coefficients of 21.45 ± 0.7 and 8.06 ± 4.19 μm2/s,
respectively (Figs. 4A–B and Table S1). However, in theFigure 3 Interaction between the FGF2-activated MAPK path-
way and HIF-1α in hypoxic hBMSCs. (A) FGF2 does not perturb the
sensitivity of hBMSCs to oxygen. FGF2-naïve and FGF2-cultured
hBMSCs were maintained under normoxic conditions or exposed
to various oxygen levels as indicated in the figure. Whole cell
lysates were tested for HIF-1α accumulation by immunoblot.
Nucleolin was used as loading control. (B) Densitometry analysis
of Fig. 3A. Loading control-normalised data of FGF2-naive (▯)
and FGF2-cultured (▮) hBMSCs are expressed as fold change of
normoxic cultures. (C–D) FGF2 induces HIF-1α basal expression
indirectly without disturbing transcriptional feedback regulation.
(C) Analysis of HIF-1α mRNA levels of FGF2-naive (▯) and
FGF2-cultured (▮) hBMSCs exposed to hypoxia. HIF-1α mRNA
levels were measured by real time RT-PCR. Data are expressed as
mean fold change to FGF2-naïve normoxic cultures ± SD (n = 3).
(D) Analysis of HIF-1α mRNA levels of FGF2-naïve cells treated
with FGF2 as indicated in the figure. HIF-1α mRNA levels were
measured by real time RT-PCR. Data are expressed as mean fold
change to FGF2-naïve normoxic cultures ± SD (n = 3). (E) HIF-1α
and phospho-ERK1/2 co-localise in hypoxic hBMSCs. Proximity
ligation assay (PLA) was carried out in untreated normoxic (E1–E3)
and FGF2-treated hypoxic (E7–E9) FGF-naïve hBMSCs at 30 min
post-exposure using phospho-specific ERK1/2 and HIF-1α-specific
primary antibodies. As positive control, stabilisation and dimer-
ization of HIF-1α with HIF-1β was induced with 1 mM DMOG for
60 min (E4–E6). PLA was carried out in DMOG-treated FGF-naïve
cells using HIF-1α- and HIF-1β-specific primary antibodies. Images
were taken using 40× water immersion objective lens. Scale bar:
24 μm.
Figure 4 FGF2 enhances HIF-1α activity in hypoxic hBMSCs. (A) FGF2 reduces nuclear diffusion of HIF-1α and facilitates the
formation of multiprotein complexes. Live cell fluorescence correlation spectroscopy (FCS) of eGFP-tagged HIF-1α was carried out
using FGF2-naïve (□), FGF2-treated (■) and FGF2 + U0126-treated (chequered boxes) U-2 osteosarcoma (U-2 OS) cells from 3
independent experiments. Data are presented as median (bold line) with the first and third quartiles (top and bottom of boxes) and
minimum/maximum values (negative/positive bars). (B) FGF2 increases the proportion of cells with complexed HIF-1α. Using
molecular diffusion data, the molecular mass of the HIF-1α species were calculated (Table S1). Data were clustered according to the
molecular masses representing either monomeric (□) or complexed (■) HIF-1α species. (C) FGF2 enhances in vitro HIF-1α
DNA-binding activity of nuclear lysates of hBMSC. Normoxic and hypoxic FGF-naive (□) and FGF2-cultured (■) hBMSCs were screened
for HIF-1α DNA binding activity at time points indicated in the figure. Data are expressed as fold change to values measured in
normoxic cultures ± SD (n = 3). (D) FGF2 enhances HIF-1α-regulated VEGF-A induction in hypoxic hBMSCs. VEGF-a mRNA levels were
measured by real time RT-PCR in FGF2-naïve (□), FGF2-treated (■) and FGF2 + U0126-treated (chequered boxes) hBMSCs exposed to
hypoxia for times indicated in the figure. Data are expressed as mean fold change to FGF2-naïve normoxic cultures ± SD (n = 3).
654 Z. Fábián et al.majority of the examined cells (83.3%) DeGFP-HIF-1α remained
comparable to that of the normoxic cells (Fig. 4B). The
maximum reduction of DeGFP-HIF-1α was observed at 8 h
post-exposure (Fig. 4A) when approximately one-third of
the cells showed slow or very slow components with the
mean DeGFP-HIF-1α = 10.68 ± 3.75 μm2/s while 2/3 of the cells
were still closer to the normoxic counterparts (DeGFP-HIF-1α =
45.79 ± 9.95 μm2/s) (Fig. 4B and Table S1). Reduction of the
HIF-1α diffusion was resolved by 12 h post-exposure when
80% of the cells had fast components and only 10% of
the cells retained slow or very slow HIF-1α species (Fig. 4B).
In contrast, FGF2-treated hypoxic cells showed prompt
and significant reduction of DeGFP-HIF-1α as early as 2 h
post-treatment (Fig. 4A). The proportion of the cells
with fast components (DeGFP-HIF-1α = 45.11 ± 12.8 μm2/s)
was reduced to ~70% and approximately 25% of the cells
showed slow diffusion components with DeGFP-HIF-1α = 9.15 ±
4.56 μm2/s (Fig. 4B and Table S1). This was further
increased by 4 h post-treatment when 58% of the cells
showed slow species (DeGFP-HIF-1α = 9.03 ± 4.48 μm2/s)(Fig. 4B). Unlike FGF-naïve cells, however, the maximal
reduction of HIF-1α diffusion was resolved between 4 and
8 h post-exposure (Fig. 4A). The proportion of the cells with
fast species of HIF-1α was increased to 75% and only 10%
displayed very slow diffusing forms (DeGFP-HIF-1α = 44.57 ±
10.7 and 9.44 ± 4.98 μm2/s, respectively) by 8 h post-
exposure (Fig. 4B and Table S1). We found no significant
difference between the nuclear diffusion of HIF-1α in
FGF2-naïve and FGF2-treated cells at 30, 60 and 90 min
post-exposure (data not shown). In addition, we did not
detect any change in HIF-1α diffusion within the cytoplasm
irrespectively of the FGF2 status of the cells (data not
shown). Pre-treatment of the FGF2-treated cells with U0126
reversed the diffusion rate of eGFP-HIF-1α to similar levels
to that of the FGF2-naïve cells at 2, 8 and 12 h post-exposure
with mean DeGFP-HIF-1α values of 42.7 ± 17.4, 51.7 ± 12.0
and 52.0 ± 7.9 μm2/s, respectively (Fig. 4A). Interestingly,
at 4 h post-exposure, we detected slow diffusion species
of eGFP-HIF1α with the diffusion rate of 28.0 ± 17.6 μm2/s.
It is noteworthy, however, that in U0126-treated cultures,
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signal-to-noise ratio in only 22% of the examined cells
and this phenomenon was particularly pronounced at 2 and
4 h post-exposure. Using our FCS data combined with
the reference diffusion coefficient of the 27 kDa eGFP and
the assumption of the approximately spherical shape of
the molecular objects in question, we also calculated the
molecular mass of eGFP-HIF-1α-containing molecular struc-
tures (Table S1). Our calculations showed dramatic differ-
ences in the molecular mass of HIF-1α-containing complexes
in the presence or absence of FGF2. In FGF2-treated
cells, significantly higher molecular masses (738.4 MDa)
were calculated as early as 2 h post-exposure compared to
the FGF2-naïve cells. Furthermore, HIF-1α species were
more homogenous and the frequency of HIF-1α-containing
mega Dalton complexes was higher in the presence of FGF2
(Table S1). To test if the alterations in its diffusion correlate
with the DNA-binding activity of HIF-1α in hBMSCs as well,
we measured the amount of HIF-1α bound to its consensus
sequence in the promoter of the erythropoietin gene using
nuclear lysates of both FGF2-naïve and FGF2-treated hBMSC
cultures (Fig. 4C). In normoxic conditions, comparable
amount of HIF-1α activity was measured in both cultures
that steadily increased in hypoxia to the maximum DNA-
binding activity at 8 h post-exposure. This was then followed
by moderate decrease in DNA-bound HIF-1α levels. In
FGF2-cultured cells, however, the amount of the DNA-
bound form of HIF-1α was increased more robustly showing a
3–4 fold increase compared to the FGF2-naïve cells over the
first 2 h of the hypoxic exposure. Peak HIF-1α DNA-binding
activity was observed between 4 and 8 h post-treatment
followed by a slight decrease between 8 and 24 h post-
exposure. The difference between the FGF2-naïve and
treated cultures, however, was maintained over the first
24 h of the hypoxic exposure. To confirm these data in a
physiologically more relevant context, we monitored the
expression of the vascular endothelial growth factor-alpha
(VEGF-A) gene, a known HIF-1α target, in hypoxic hBMSCs
in the presence or absence of FGF2 and U0126 (Fig. 4D).
FGF2-naïve cultures increased VEGF-A expression very
moderately over the first 24 h of hypoxic exposure showing
an approximately 2-fold maximum induction after 12 h post
exposure. In contrast, FGF2-cultured hBMSCs responded
more promptly to hypoxia by inducing VEGF-A as early as
2 h post-exposure steadily increasing mRNA levels over the
first 24 h of the hypoxic exposure. The use of U0126 reversed
this response similarly to that of the FGF2-naïve cultures and
this effect was particularly pronounced at the early time
points up to 16 h post-exposure.Discussion
In vitro, hBMSCs are capable of differentiating into a variety
of cell types including osteo-, chondro- and adipocytes
(Pittenger et al., 1999). This fuelled the idea of their use
for regenerative cellular therapy of a wide range of human
pathologies including those that affect tissues of the skeletal
system (Bianco et al., 2001). Although the related patholog-
ical conditions may have distinct pathogenesis, hypoxia is
one of the few known pathological factors. hBMSCs naturally
reside in a poorly oxygenised microenvironment making themparticularly attractive for cellular therapy of conditions either
affecting poorly vascularised tissues e.g. cartilage or related
to pathological forms of hypoxia like the metabolic hypoxia in
chronic inflammatory diseases like osteoarthritis (Chow et al.,
2001; Tondevold et al., 1979).
During their ex vivo expansion, donor cells are kept in
conditions fundamentally different from their natural niche in
terms of the oxygen levels or increased mitogenic pressure.
The impact of the ex vivo expansion on the hypoxic adaptation
of hBMSCs, however, has remained unexplored. Here, we
found that, in vitro, the hypoxia-adaptive responses are
enhanced in the presence of FGF2 including the robust
induction of genes encoding glycolytic enzymes, intracellular
homeostasis regulators, glucose transporters or VEGF, sug-
gesting that FGF2-treated hBMSCs may adapt to the hypoxic
milieu more efficiently.
As FGFs are primarily considered mitogenic factors, our
data also indicate the direct link between mechanisms
controlling proliferation and hypoxic adaptation of hBMSCs.
Indeed, we identified the ERK pathway to convey FGF2
signals. Interestingly, similar to established cell lines, we
found that hypoxia also activates the distal elements of the
ERK pathway in hBMSCs and the dynamics of this activation
is similar to that of the FGF2 questioning the mechanism
of action of the FGF2 on the hypoxic response in hBMSCs
(Minet et al., 2000). The more sustained ERK activation
during the co-stimulation by FGF2 and hypoxia compared
to the dynamics observed upon the activation by only a
single stimulus may provide an explanation for this question.
Indeed, differential dynamics of the ERK pathway may lead
to distinct biological effects as was shown in other model
systems (Yoon and Deisboeck, 2009). In the case of hBMSCs,
the simultaneous presence of the two stimuli led to higher
cell numbers during their in vitro expansion. Since we found
no statistical difference in the number of the colony forming
unit fibroblasts in hBMSC cultures treated with any combi-
nation of FGF2 and hypoxia/normoxia (data not shown), we
concluded that the higher yield in cell numbers are primarily
due to upregulation of the proliferation.
Although the relationship between HIF-1 and the ERK
pathways has already been reported in established cell lines,
the nature of this interaction remained obscure as reports
indicated both direct and indirect effects of ERK activation on
HIF-1 activity (Bilton and Booker, 2003; Mylonis et al., 2008;
Sang et al., 2003). For the first time, we approached this
question using live cell fluorescence correlation spectroscopy
and measured the mobility dynamics of the eGFP-tagged
HIF-1α in the context of the FGF2-induced ERK activation. As
a result, we observed interesting differences in the diffusion
coefficients of eGFP-HIF-1α (DeGFP-HIF-1α) comparing both
normoxic-hypoxic as well as FGF2-naïve and FGF2-treated
cells. Despite the Stokes–Einstein relation that predicts
eGFP-tagged molecules diffusing more slowly than the
standalone eGFP, we found the DeGFP-HIF-1α increased by a
factor of 1.3 over the diffusion coefficients of eGFP (DeGFP) in
normoxic cells. DeGFP was calculated using experimental
curves fitted to the one component free diffusion model
that resulted in DeGFP comparable to literature values
(Jeyasekharan et al., 2010). This led us to speculate that
the elevated DeGFP-HIF-1α measured in normoxic cells may
represent active transport mechanisms rather than Brownian
motion. Indeed, recent reports suggested that the VHL protein
656 Z. Fábián et al.interacts with microtubules through kinesin-2 (Carbonaro et
al., 2012). Under hypoxia, the elevated basal DeGFP-HIF-1α was
significantly reduced. Theoretically, reduction of the nucleo-
plasmic mobility could have accounted for the formation of
protein complexes, molecular crowding, transient intermo-
lecular interactions or obstructions by immobile nuclear
structures (Bancaud et al., 2009; Fritsch and Langowski,
2011). The latter one is believed to result in very slow species
(0.1–2 μm2/s) but this was not observed in our FGF2-naïve
hypoxic cells (Jeyasekharan et al., 2010). Moreover, since our
data fitted the one component free diffusion model with
residual fit close to zero (Fig. S2), we excluded bothmolecular
obstruction and crowding and speculate that the most likely
cause of the DeGFP-HIF-1α reduction is complex formation. Using
our FCS data, we also calculated the molecular masses of the
eGFP-HIF-1α-containing structures. These calculations sug-
gest that HIF-1α may be in different molecular complexes in
the nucleus depending on the activation status of the ERK
pathway. Our data indicate that the activation of the ERK
pathway not only contributes to the temporal regulation of
the formation of HIF-1α-containing nuclear complexes but
also to the molecular compositions of the same resulting in
significant impact on the regulatory functions of HIF-1α and,
consequently, the adaptive response to hypoxia (Fig. 5) (Sang
et al., 2003; Semenza, 2007; Wotzlaw et al., 2007).
In vitro, the hypoxic exposure of hBMSCs positively
influences their differentiation capacity, metabolism or
senescence (Dos Santos et al., 2010; Grayson et al., 2007;
Jin et al., 2010). In our current study, we identified the
FGF2-mediated activation of the ERK pathway as a potential
regulator of the HIF-1α-mediated hypoxic response of hBMSCs.Figure 5 ERK pathway has dual effect on the transcriptional
regulation of the hypoxia response in hBMSCs. Our data indicate
that FGF2 and hypoxia both activate the ERK pathway. In short
term, this activation facilitates the complex formation and DNA
binding of the stabilised HIF-1α and represents a direct physical
link between the ERK- and HIF-1α-mediated molecular events
(continuous line). Long term FGF2 treatment, however, has an
additional but indirect effect on the HIF-1 machinery by the
elevation of the basal expression of HIF-1α gene in normoxic
cells (dashed line).However, our finding that the ERK pathway is utilised by both
stimuli raises the question if hypoxia has effects on hBMSCs
similar to those of FGF2 that, while apparently not interfering
with the differentiation capacity of hBMSCs in vitro, was
shown to have an adverse effect on the hBMSC-mediated
ectopic formation of the hematopoetic microenvironment
in vivo (Sacchetti et al., 2007). Although FGF2 and hypoxia
appeared to be synergistic on the proliferation of our hBMSCs
in vitro, the functionality of the FGF2-cultured hypoxic
hBMSCs needs to be confirmed in more appropriate in vivo
models. Understanding the underlying regulatory mechanisms
of the two stimuli, however, may contribute to the better
determination of the culturing conditions for hBMSCs.Conclusion
Our observations strongly indicate that the activation status
of the ERK pathway has an important role in the hypoxic
response of hBMSCs. As we found the ERK pathway to be the
immediately responding signalling machinery to the mitotic
stimulus of FGF2 and that the donor-to-donor heterogeneity
in terms of proliferation and differentiation capacity is a
well-known feature of the in vitromaintained hBMSC cultures,
we hypothesise that the different proportions of the prolifer-
ating species in any individual bone marrow aspirates may
be a critical factor to the post-transplantation fate of the
hBMSC populations in the hypo- or anoxicmilieu. Similarly, the
impact of the ex vivo manipulations on the status of the ERK
pathway may also be important when cells are considered to
be used in cellular therapy of medical situations with different
levels of hypoxia.
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